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Long-term follow-up of these screen-diagnosed cases showed that 
the 10-year Kaplan-Meier survival rates for all cases, regardless of 
stage and treatment, was 80%. If the cancer was in clinical Stage I and 
promptly resected, the 10-year rate was 92% (11). Concerns expressed 
about leadtime, length, and overdiagnosis bias were addressed in our 
responses to the letters to the Editor (12). We do have a comparison 
group, but at the time of treatment where it is appropriate and our com-
parisons do not have lead time bias (12).
Bach et al. (13) used a model to predict deaths in from lung cancer and 
applied it to 3 small studies of CT screening in asymptomatic people 
at risk of lung cancer and found that there was no reduction in deaths 
by screening. They did not distinguish between baseline and annual 
screening. Most importantly, they included more than 5 deaths in symp-
tomatic people and at least another 6 who did have any per protocol 
imaging and biopsy. Had even 5 of these inadmissible enrollees been 
excluded, the conclusions would have been reversed as there would 
have been a statistically signiﬁcant reduction in deaths. Thus, Bach 
et al.’s ﬁndings when correctly presented conﬁrmed the ﬁndings of 
I-ELCAP.
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Bronchioloalveolar carcinoma (BAC) is a malignant epithelial tumor 
of peripheral airways that spreads along the alveolar surfaces without 
destroying underlying alveolar structures in a pattern that is referred of 
growth that is referred to as “lepidic”. BAC is relatively recent concept 
with the term “bronchioloalveolar carcinoma” only introduced in 1960 
as “...well-differentiated adenocarcinomas primary in the periphery 
of the lung beyond a grossly recognizable bronchus, with a tendency 
to spread chieﬂy within the conﬁnes of the lung by aerogenous and 
lymphatic routes...”(1). The concept has evolved largely on the basis of 
data accumulated through Japanese studies indicating that small tumors 
(<2 cm, size often detected by CT screening) BAC without evidence 
of invasion have a uniformly excellent prognosis(2). On the basis of 
these data BAC was redeﬁned by the WHO as an in situ lesion without 
evidence of stromal invasion. This reclassiﬁcation been criticized for 
several reasons:
1. The data on which it was based was derived from careful studies 
using processing methods that are not the standard of practice in 
Western countries. The Japanese data may not be reproducible in 
less rigorous non-research environments in the West.
2. It is now known that the molecular proﬁle of lung cancer in Japan is 
different that in the 
West and more frequently includes EGFR mutation and less frequent 
Ki-ras mutation suggesting that tumors in Japan may be biologically 
different than those in the West.
3. The importance of the distinction between mucinous and non-muci-
nous tumors and relationship between classical BAC and other more 
recently described forms of intra-alveolar growth patterns such as 
papillary and micropapillary is only now being appreciated.
These issues have special relevance to ongoing CT trials and their 
relevance to biological modeling and clinical management will be 
discussed.
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Background
The practice of VATS lobectomy for primary surgical therapy of early 
stage non-small cell lung cancer (NSCLC) is increasing, but has not be-
come widespread practice despite indications that the procedure is safe 
and oncologically acceptable in patients with stage I disease. Limita-
tions of minimally invasive surgical (MIS) approaches for performance 
of major thoracic procedures include two-dimensional imaging, an 
unsteady camera platform, and limited maneuverability of instruments 
used through small non-rib spreading incisions. The da Vinci® Surgi-
cal System (Intuitive Surgical®, Sunnyvale, CA) is an FDA-approved 
telerobotic system designed to address these limitations, employing the 
Insite® vision system with a true three-dimensional (3-D) endoscope 
providing a high-resolution, binocular view of the surgical ﬁeld and the 
EndoWrist® instrument system capable of seven degrees of freedom 
and two degrees of axial rotation in order to replicate human wrist-
like movements. Because there was little experience with telerobotic 
assistance for VATS lobectomy, we developed a technique for robotic 
assistance and report our experience employing the da Vinci® Surgi-
cal System. We have reviewed the indications for the procedure, the 
